Home Corvia Medical

Corvia Medical

First Japanese Patients Randomized In Corvia Medical’s REDUCE LAP-HF II Global Clinical Trial For Heart Failure

Pivotal study investigates the Corvia InterAtrial Shunt Device (IASD®) for heart failure

Corvia Medical and physIQ Partner in Global Phase 3 Heart Failure Clinical Trial to Leverage Novel Digital Endpoints

The clinical trial is designed to evaluate the clinical efficacy of Corvia’s InterAtrial Shunt Device (IASD®) in patients with heart failure and is enrolling patients at more than 100 sites worldwide. Of note, the pivotal Phase 3 study design mirrors commentary within a recent FDA Public Workshop and FDA Draft Guidance for Industry related to using biosensor data.